International nonproprietary names for monoclonal antibodies: an evolving nomenclature system
Open Access
- 18 May 2022
- journal article
- other
- Published by Taylor & Francis in mAbs
- Vol. 14 (1) , 2075078
Abstract
Appropriate nomenclature for all pharmaceutical substances is important for clinical development, licensing, prescribing, pharmacovigilance, and identification of counterfeits. Nonproprietary names that are unique and globally recognized for all pharmaceutical substances are assigned by the International Nonproprietary Names (INN) Programme of the World Health Organization (WHO). In 1991, the INN Programme implemented the first nomenclature scheme for monoclonal antibodies. To accompany biotechnological development, this nomenclature scheme has evolved over the years; however, since the scheme was introduced, all pharmacological substances that contained an immunoglobulin variable domain were coined with the stem -mab. To date, there are 879 INN with the stem -mab. Owing to this high number of names ending in -mab, devising new and distinguishable INN has become a challenge. The WHO INN Expert Group therefore decided to revise the system to ease this situation. The revised system was approved and adopted by the WHO at the 73rd INN Consultation held in October 2021, and the radical decision was made to discontinue the use of the well-known stem -mab in naming new antibody-based drugs and going forward, to replace it with four new stems: -tug, -bart, -mig, and -ment.Keywords
Funding Information
- The author(s) reported there is no funding associated with the work featured in this article
This publication has 8 references indexed in Scilit:
- International Nonproprietary Names (INN) for novel vaccine substances: A matter of safetyVaccine, 2022
- The harmonization of World Health Organization International Nonproprietary Names definitions for cell and cell-based gene therapy substances: when a name is not enoughCytotherapy, 2021
- The INN global nomenclature of biological medicines: A continuous challengeBiologicals, 2019
- The INNs and outs of antibody nonproprietary namesmAbs, 2015
- The therapeutic monoclonal antibody marketmAbs, 2015
- Immunogenicity of protein therapeutics: The key causes, consequences and challengesSelf/Nonself, 2010
- The immunogenicity of therapeutic proteins.2010
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975